Epidemiology
Although.the.overall.prevalence.of.OAB.is.similar.between. men.and.women,.there.are.sex-specific.differences.in.the. prevalence.of.various.symptoms.within.the.OAB.complex. 6, 7 . Anatomical.and.physiological.differences.in.the.lower.urinary.tract.of.males.and.females.may.help.to.explain.these. variations. 7 .Overall,.OAB.prevalence.rates.in.large.population-based.studies.range.from.7-27%.in.men.and.9-43%. in. women. [8] [9] [10] [11] [12] [13] [14] [15] . Interestingly,. a. proportion. of. OAB. cases. (37-39%).remit.during.a.given.year,.but.the.majority.of. patients.have.persistent.symptoms. 16, 17 . The.EPIC.study.is.one.of.the.largest.population-based. surveys.that.examined.the.prevalence.of.lower.urinary.tract. symptoms.(LUTS).and.OAB..The.study.had.over. 19 .000.participants.and.showed.an.overall.OAB.prevalence.of.11.8%. (10.8%.in.men.and.12.8%.in.women).using.ICS.definitions. 12 .
The.National. 
Treatment
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Management of fluid intake

Summary and recommendations: Second-line treatment of OAB should include the use of oral AMs, transdermal oxybutynin or oral beta-3 adrenoceptor agonist (Evidence strength Grade A). The lowest recommended dose should first be prescribed, followed by dose increases in order to obtain the best clinical improvement while monitoring for adverse events (Evidence strength Grade B). If the initial selected drug is not tolerated or does not provide adequate symptom relief, patients should be offered an alternative medication, preferably with a different mechanism of action (Expert opinion). The adverse event profile and possible contraindications should be considered when prescribing the drug of choice as second-line treatment (Expert opinion). Immediate release formulations of AMs should be avoided if other formulations are available (Evidence strength Grade A). Patients who remain incontinent after the initial treatment with an AM could be offered combination treatment with solifenacin and mirabegron (Evidence strength Grade C). Recommended doses of drugs are presented in
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